The therapeutic potential of restoring this pathway is supported by the successful use of the semisynthetic FXR agonist obeticholic acid, which has antifibrotic effects in patients with MASH (77). This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.